Braeburn

Braeburn Inc. specializes in developing and commercializing medications for serious central nervous system disorders, with a primary focus on opioid addiction. This chronic condition leads to significant changes in brain structure and function, presenting substantial challenges for affected individuals. Braeburn's flagship product is BRIXADI, an extended-release injectable formulation of buprenorphine designed to treat moderate to severe opioid use disorder. The company aims to offer innovative therapies with personalized dosing and delivery methods, addressing the growing crisis of opioid addiction. Founded in 2012 and headquartered in Plymouth Meeting, Pennsylvania, Braeburn is committed to providing solutions that mitigate the serious consequences of opioid use disorder for patients, healthcare professionals, and society as a whole.